2024-05-23T12:38:55.997Z

ASTuTE

ASTuTE
Prostate cancer

Shared decision making using multimodal Artificial Intelligence (MMAI) with digital histopathology for Androgen Deprivation Therapy (ADT) use in men with intermediate risk prostate cancer managed with standard of care radiotherapy.

Shared decision making using multimodal Artificial Intelligence (MMAI) with digital histopathology for Androgen Deprivation Therapy (ADT) use in men with intermediate risk prostate cancer managed with standard of care radiotherapy.

Trial overview

Disease Site

Prostate Cancer

Cancer Specialty

Radiation Oncology

Phase

II

Age

18 +

Trial Identifiers
Study details

This study aims to assess how a new test (ArteraAI) that uses artificial intelligence to analyse prostate tumour samples to predict patient outcomes and suitable treatment options impacts the treatment recommendations that doctors make for their patients with prostate cancer.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.